Our study of the antibody response against MAGEA4/10 proteins in patients with melanoma at different stages of disease revealed highest number of strongly responding patients among stage II, but no response in stage IV patients [37], which allows us to suggest that MAGEA-EVs may have a role in modulation of immune response. This evidence concerns the gene MAGEA4 and melanoma.